• ADC Therapeutics SA ADCT.N reported a quarterly adjusted loss of 29 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.03. The mean expectation of six analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -51 cents to -28 cents per share.

• Revenue rose 0.7% to $16.91 million from a year ago; analysts expected $19.01 million.

• ADC Therapeutics SA's reported EPS for the quarter was a loss of 29 cents​.

• The company reported a quarterly loss of $30.73 million.

• ADC Therapeutics SA shares had fallen by 20.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for ADC Therapeutics SA is $8.00

This summary was machine generated from LSEG data March 27 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)